Privigen® Dosing for Patients With PI and ITP
For patients with PI, the usual dose of Privigen® is 200–800 mg/kg, administered every 3 to 4 weeks. Doses should be adjusted to achieve the desired serum trough levels and clinical response. An optimum target serum IgG trough level has not been established in randomized, controlled clinical studies.
Privigen® is effective in preventing acute serious infections in patients with PI, because it supplies a broad spectrum of IgG antibodies against viruses, bacteria, and their toxins.
The recommended initial infusion rate is 0.5 mg/kg/min (0.005 mL/kg/min). If the infusion is well tolerated, the rate of administration may be gradually increased to 8 mg/kg/min
(0.08 mL/kg/min).
Dosing for Patients Transitioning From Lyophilized to Liquid Ig
When transitioning patients from one Ig product to another, such as from lyophilized to liquid Ig products, always start at the minimum rate of infusion. The initial infusion rate is
0.5 mg/kg/min (0.005 mL/kg/min). The patient’s vital signs should be monitored carefully throughout the infusion for side effects. Click here to download a comparison of our liquid and lyophilized products.
If side effects occur, the infusion should be stopped until the symptoms subside. The infusion may then be resumed at a lower rate that is comfortable for the patient.
Dosing for Patients With Chronic ITP
Privigen® is indicated in chronic ITP, rapidly increasing platelet counts, and inducing a regression of bleeding. The recommended dose is 1 g/kg intravenously daily for 2 consecutive days, for a total of 2 g/kg
The recommended initial infusion rate is 0.5 mg/kg/min (0.005 mL/kg/min); if well tolerated, the rate may be increased gradually to a rate of 4 mg/kg/min (0.04 mL/kg/min). As with all IVIg therapy, it should be administered at the minimum infusion rate practicable in patients judged to be at risk of renal dysfunction or thrombotic events, and patients with pre-existing renal insufficiency should not be volume-depleted when initiating therapy.
